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Aims: Daily practice shows that patients with pre-capillary pulmonary hypertension (PH) may develop a
secondary elevation of their pulmonary artery wedge pressure (PAWP) above the 15 mm Hg limit. This
phenomenon has not been precisely described yet. We aimed at identifying factors present at initial diagnosis
that could predict this secondary elevation of PAWP, its possible causes and impact on survival.
Methods and results: We included 90 patients followed between 2004 and 2011 in our center. At the end of
follow-up (3.0 ± 1.6 years), patients were divided into two groups according to the successive PAWP
measurements (always ≤ 15 mm Hg or N15 mm Hg on at least one right heart catheterization (RHC)).
Demographical, biological, echographic and hemodynamical data at ﬁrst RHC were compared. Possible causes
for PAWP N15 mm Hg were searched. A Kaplan–Meier method was used to assess differences in survival. One
third of our cohort developed an elevation of PAWP above 15 mm Hg and patients with idiopathic pulmonary
arterial hypertension were at smaller risk (OR 0.20 [0.05–0.82]; p = 0.026). We did not identify any other
baseline predictive factors. We highlighted several possible causes and factors that may unmask an underlying
left ventricular diastolic dysfunction. Survival was not different between both groups (p = 0.42).
Conclusion: Secondary elevation of PAWP in pre-capillary PHwas frequent but less observed in idiopathic PH.We
detailedmany possible causes that can be sought, many ofwhichmay be related to an underlying left ventricular
diastolic dysfunction.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Pulmonary Hypertension (PH) is a life threatening disease charac-
terized by a progressive increase of pulmonary blood pressure and aody mass index; BNP, brain na-
ndex; CO, cardiac output; dPAP,
re gradient; ECG, electrocardio-
left bundle branch block; LVDD,
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versity hospital of Caen, Avenue
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).
land Ltd. This is an open access articlepulmonary vascular remodeling [1] that often leads to right ventricular
failure and death. Pre-capillary PH is deﬁned by a mean pulmonary
arterial pressure (mPAP) ≥25 mm Hg and a pulmonary artery wedge
pressure (PAWP) ≤15 mm Hg. It is classically opposed to post-
capillary PH due to left heart disease.
Nevertheless, daily practice shows that, regardless of the initial
etiology of pre-capillary PH, some patients develop a secondary
elevation of their pulmonary artery wedge pressure during follow-
up. In a recent study from the REVEAL registry, a PAWP N15 mm Hg
was measured in 30% of PAH patients on successive right heart
catheterizations (RHC), regardless of initial PAWP [2]. For the time
being, the characteristics and the evolution of pre-capillary PH
patients with a secondary increase of PAWP has not been described
yet. Through this observational study, we aimed at deﬁning demo-
graphic, biological and hemodynamic markers present at initial
diagnosis of pre-capillary PH that could predict this secondary
elevation of PAWP and at analyzing its possible causes. Furthermore,
we evaluated whether this evolution of the disease towards a mixed
form of PH had an impact on all-cause mortality.under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Fig. 1. Flow chart of patient section process.
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2.1. Design
This is a descriptive, monocentric study with retrospective analysis
of a prospective acquired PH regional register.2.2. Study population
We screened 182 ﬁles of patients diagnosed at our Regional
Centre for Pulmonary Hypertension between May 2004 and March
2011. All patients were also included prospectively in the French
registry for Pulmonary Hypertension [3]. They all gave written
informed consent.
We included all patients who had ≥2 RHC during follow-up and
an initial RHC showing pre-capillary PH according to current inter-
national guidelines [4,5] deﬁned by a mean pulmonary arterial
pressure (mPAP) ≥25 mm Hg and a PAWP ≤15 mm Hg at rest.
Consequently, patients belonged to groups 1, 3, 4 and 5 of the Dana
Point classiﬁcation [4,5]. All patients had pulmonary vascular
resistance (PVR) N3 WU. We excluded patients that had only one
RHC during follow-up, adults with congenital heart defects, patients
whose ﬁrst RHC was not performed at our hospital as hemo-
dynamic curves could not be reviewed, those with a ﬁrst RHC
showing a litigious PAWP or a PAWP ≥15 mm Hg at reviewing he-
modynamic curves and patients who had undergone pulmonary
thromboendarterectomy.
Cardiovascular risk factors and medical history, treatment, elec-
trocardiogram (ECG), six minute walking test (6MWT), biological
parameters and hemodynamical parameters were all recorded on
the day of the ﬁrst RHC. Biological testing was made for renal func-
tion, brain natriuretic peptide (BNP by ELISA) and troponin (TnI by
ELISA). Transthoracic echocardiography (TTE) at initial diagnosis
could not always be performed on the same day as RHC, which
explains why only left ventricular ejection fraction (LVEF) using
Simpson's biplane method, pericardial effusion and echographic
signs of ventricular interdependency were taken in account.2.3. Cardiac catheterization
Patients underwent standard RHC using a Swan–Ganz catheter with
brachial or femoral venous access. The zero level was placed at the
midthoracic line. The following measurements were obtained: heart
rate, systolic pulmonary arterial pressure (sPAP), diastolic pulmonary
arterial pressure (dPAP), mPAP, PAWP, right ventricular end-diastolic
pressure (RVEDP), right atrial pressure (RAP), cardiac output (CO)
determined by thermodilution (mean of three consecutive measure-
ments without N10% variation), cardiac index (CI), and PVR calculated
from the standard formula PVR = (mPAP-PAWP)/CO. Transpulmonary
gradient (TPG) was deﬁned as mPAP-PAWP and diastolic pressure
gradient (DPG) as dPAP-PAWP. Vasoreactivity testing using inhaled
nitric oxide was performed on the ﬁrst RHC. PAWP was measured
at end-expiration. Hemodynamic curves obtained from RHC were
anonymously reviewed by four specialists (E.B., R.S., V.R. and J.W.H.).
Discrepancies in reviewing were resolved by consensus.2.4. Follow-up
Patientswere followed on a regular basis with a clinical examination
every 3 months plus an annual daytime hospitalization with 6MWT,
ECG, pulmonary function testing, RHC, TTE and biologic samples. RHC
was performed after every dose change of PAH speciﬁc treatments.
Any acute pathological manifestation would lead to hospitalization,
necessary complementary examinations and adaptation of treatment.
Long term treatment was started and adapted according to the inter-
national guidelines [4,5]. Patients who had a PAWP N15 mm Hg during
follow-up and hadmultiple (≥3) cardiovascular risk factors underwent
a coronary angiography.
Survival follow-upwas performed on June 1st, 2012 by telephone in-
terview with the general practitioner or the patient. All-cause mortality
was used for analyses. At this time, we divided patients into two differ-
ent groups: GroupAwas composed of patientswith a strict pre-capillary
PAH (i.e. with a measurement of PAWP ≤15 mm Hg on every RHC
performed during follow-up) and Group B included patients who had
at least one RHC with a PAWP N15 mm Hg during this period of time.
Table 1
Characteristics at ﬁrst diagnosis RHC in the overall population.
Data at ﬁrst RHC Overall population
(n = 90)
Group A
(n = 60)
Group B
(n = 30)
p
Age 65.2 ± 14.6 65.2 ± 15.7 65.2 ± 12.3 0.99
Female patients 49 (54.4%) 34 (56.7%) 15 (50%) 0.55
Cardiovascular risk factors
Systemic hypertension 49 (54.4%) 33 (55%) 16 (53.3%) 0.88
Diabetes mellitus 19 (21.1%) 13 (21.7%) 6 (20%) 0.85
Dyslipidemiaa 45 (50%) 28 (46.7%) 17 (56.7%) 0.37
Smokingb 26 (28.9%) 18 (30%) 8 (26.7%) 0.74
Body Mass Index (kg/m2) 26.8 ± 5.7 26.5 ± 6 27.3 ± 5.1 0.53
History
Sleep apnea 8 (8.9%) 6 (10%) 2 (6.7%) 0.71
Coronary artery disease 14 (15.6%) 10 (16.7%) 4 (13.3%) 0.41
SVT 13 (14.4%) 7 (11.7%) 6 (20.7%) 0.34
Peripheral vascular disease 6 (6.7%) 4 (6.7%) 2 (6.7%) 1.00
Origin of PH
Group 1 54 (60%) 37 (61.7%) 17 (56.7%) 0.64
Group 3 11 (12.2%) 7 (11.7%) 4 (13.3%) 0.82
Group 4 18 (20%) 11 (18.3%) 7 (23.3%) 0.57
Group 5 7 (7.8%) 5 (8.3%) 2 (6.7%) 0.78
Clinical presentation
WHO I + II 24 (26.7%) 16 (26.7%) 8 (26.7%) 1.00
WHO III 50 (55.5%) 32 (53.3%) 18 (60%) 0.54
WHO IV 16 (17.8%) 12 (20%) 4 (13.3%) 0.43
6 min Walking Test (meters) 299.7 ± 138.9 296.2 ± 146.8 306.24 ± 125.15 0.76
SVT on initial ECG 6 (6.7%) 3 (5%) 3 (10%) 0.40
Complete RBBB 12 (13.3%) 6 (10%) 6 (20%) 0.20
Complete LBBB 5 (5.6%) 3 (5%) 2 (6.7%) 0.75
Biology
BNP (pg/mL) 454.2 ± 634.5 487.1 ± 701.1 392.8 ± 492.7 0.47
Troponin (μg/L) 0.06 ± 0.16 0.07 ± 0.19 0.05 ± 0.06 0.45
MDRD (mL/min/1.73 m2) 69.4 ± 24.1 71.3 ± 24.4 65.6 ± 23.3 0.29
Echocardiography
LVEF (%) 64.7 ± 9.22 64.7 ± 9.5 64.8 ± 8.8 0.97
Pericardial effusion 10 (11.1%) 8 (3.3%) 2 (6.7%) 0.35
Hemodynamics
Heart rate (bpm) 79 ± 14 81 ± 14 76 ± 14 0.12
sPAP (mm Hg) 75.5 ± 19.3 77.3 ± 20.1 71.9 ± 17.5 0.22
dPAP (mm Hg) 31 ± 9.9 31.9 ± 10.4 29.3 ± 8.7 0.25
mPAP (mm Hg) 47.1 ± 12.2 48.3 ± 13.1 44.7 ± 10.1 0.18
PAWP (mm Hg) 10.7 ± 2.6 10.9 ± 2.7 10.4 ± 2.4 0.42
RVEDP (mm Hg) 14.3 ± 5.6 14.6 ± 5.6 13.7 ± 5.7 0.50
RAP (mm Hg) 10.1 ± 5 10.3 ± 4.3 9.5 ± 6.2 0.48
CO (L/min) 4.6 ± 1.33 4.5 ± 1.24 4.7 ± 1.49 0.53
CI (L/min/m2) 2.54 ± 0.62 2.52 ± 0.6 2.6 ± 0.7 0.73
PVR (WU) 8.93 ± 4.74 9.3 ± 5 8.2 ± 4.2 0.28
mPAP-PCWP (mm Hg) 36.4 ± 12.5 37.4 ± 13.2 34.3 ± 10.7 0.25
dPAP-PCWP (mm Hg) 20.3 ± 10.1 21 ± 10.5 18.9 ± 9.4 0.36
SVT = supra ventricular tachycardia;WHO = world health organization functional class of dyspnea; ECG = electrocardiogram; RBBB = right bundle branch block; LBBB = left bundle
branch block; LVEF = left ventricular ejection fraction; BNP = brain natriuretic protein; MDRD = modiﬁcation of the diet in renal disease Formula; sPAP = systolic pulmonary arterial
pressure; dPAP = diastolic pulmonary arterial pressure; mPAP = mean pulmonary arterial pressure; PAWP = pulmonary artery wedge pressure; RVEDP = right ventricular end
diastolic pressure; RAP = right atrial pressure; CO = cardiac output; CI = cardiac index; PVR = pulmonary vascular resistance; WU = wood units.
a LDL (low-density lipoprotein–cholesterol) ≥1 g/L or patient under statin therapy.
b Active smoking or stopped for less than 3 years.
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used the following deﬁnitions: high cardiac output (CI ≥ 3.9 L/min/m2
or CO≥ 8 L/min), ventricular interdependence (association of respirato-
ry mitral ﬂow and aortic ejection ﬂow variation, and dilated right ventri-
cle with paradoxal septum found at TTE), coronary artery disease (CAD,
deﬁned as one or more signiﬁcant stenosis ≥70% of a coronary vessel).
2.5. Statistical analysis
Statistical analysis was performed using SAS 9.3 Software (SAS
Institute, Cary, NC). A p value of b0.05 was considered statistically sig-
niﬁcant. All continuous variables were expressed as mean values ±
standard deviation and compared using Student test. Categorical
variables were expressed as numbers of patients or percentages and
compared using χ2 test or Fischer's test if necessary. Prognostic factors
to belong to group B were determined using an initial log-rank test.Then, factors associated with group B (p ≤ 0.15) were included in a
stepwise analysis using logistic regression model and results were
expressed as relative risk with a 95% conﬁdence interval. General linear
model multivariate analysis was added to identify possible baseline
factors associated with maximal PAWP variation (i.e. the difference
between ﬁrst PAWP and maximal PAWP measured during follow-up)
in the whole population. Comparison within group B at initial RHC
and at RHC showing the ﬁrst elevation of PAWP was performed using
Student test for continuous variables and Mac–Nemar's χ2 test for
categorical variables. A Kaplan–Meier method was used to assess
differences of survival between the 2 groups and a log-rank test was
used for comparison of survival distribution. Prognostic factors for
mortality were determined using an initial log-rank test. Then, factors
associated with mortality (p ≤ 0.15) were included in a stepwise
analysis using the Cox regression model and results were expressed as
relative risk with a 95% conﬁdence interval.
Table 2
Characteristics at ﬁrst diagnosis RHC for PAH sub group.
Data at ﬁrst RHC PAH subgroup (n = 54) Group A (n = 37) Group B (n = 17) p
Age 61.3 ± 15.6 61.6 ± 15.7 60.3 ± 12.1 0.77
Female patients 34 (63%) 23 (62.1%) 11 (64.7) 0.85
Cardiovascular risk factors
Systemic hypertension 26 (48%) 17 (46%) 9 (52.9%) 0.63
Diabetes mellitus 15 (28%) 9 (24.3%) 6 (35.3%) 0.52
Dyslipidemiaa 22 (41%) 14 (37.8%) 8 (47.1%) 0.52
Smokingb 19 (35%) 14 (37.8%) 5 (29.4%) 0.54
Body Mass Index (kg/m2) 26.9 ± 5.8 26.8 ± 5.8 27.3 ± 6 0.77
History
Sleep apnea 7 (13%) 5 (13.5%) 2 (11.8%) 0.86
Coronary artery disease 7 (13%) 6 (16.2%) 1 (5.9%) 0.76
SVT 6 (11.1%) 4 (10.8%) 2 (11.8%) 0.91
Peripheral vascular disease 1 (1.9%) 1 (2.7%) 0 (0%) –
Clinical presentation
WHO I + II 13 (24%) 9 (24.3%) 4 (23.5%) 0.94
WHO III 32 (59.3%) 22 (59.4%) 10 (58.8%) 0.94
WHO IV 9 (16.7%) 6 (16.2%) 3 (17.6%) 0.96
Mean WHO 2.9 ± 0.7 2.89 ± 0.7 2.94 ± 0.7 0.89
6 min Walking Test (meters) 313.9 ± 125.3 324 ± 229.2 293 ± 114.7 0.42
SVT on initial ECG 3 (5.6%) 1 (2.7%) 2 (11.8%) 0.23
Complete RBBB 4 (7.4%) 2 (5.4%) 2 (11.8%) 0.58
Complete LBBB 2 (3.7%) 2 (5.4%) 0 (0%) –
Echocardiography
LVEF (%) 65.5 ± 9.1 65.4 ± 8.7 65.6 ± 10 0.95
Pericardial effusion 5 (9.3%) 5 (13.5%) 0 (0%) –
Biology
BNP (pg/mL) 460 ± 707 468.3 ± 780.9 442 ± 532.3 0.9
Troponin (μg/L) 0.07 ± 0.2 0.08 ± 0.23 0.05 ± 0.08 0.53
MDRD (mL/min/1.73 m2) 75.1 ± 24.8 76.3 ± 26.9 72.5 ± 20.1 0.6
Hemodynamics
sPAP (mm Hg) 77.2 ± 21.6 79.8 ± 21.9 71.6 ± 20.2 0.19
dPAP (mm Hg) 33.8 ± 11.1 35 ± 11.5 31.2 ± 9.9 0.24
mPAP (mm Hg) 49.5 ± 13.9 51.2 ± 14.7 45.9 ± 11.6 0.19
PAWP (mm Hg) 11 ± 2.7 11.1 ± 2.7 10.6 ± 2.7 0.50
RVEDP (mm Hg) 14.3 ± 6.2 14.6 ± 5.7 13.7 ± 7.3 0.62
RAP (mm Hg) 10.3 ± 5.6 10.5 ± 4.5 10.1 ± 7.7 0.83
CO (L/min) 4.6 ± 1.42 4.52 ± 1.28 4.76 ± 1.73 0.56
Heart rate (bpm) 81 ± 14 83 ± 14 77 ± 14 0.11
CI (L/min/m2) 2.54 ± 0.62 2.52 ± 0.62 2.59 ± 0.74 0.69
PVR (WU) 9.5 ± 5.42 10 ± 5.7 8.4 ± 4.7 0.30
mPAP-PCWP (mm Hg) 38.6 ± 14.4 40 ± 15 35.3 ± 12.6 0.26
dPAP-PCWP (mm Hg) 22.8 ± 11.5 23.8 ± 11.8 20.6 ± 10.9 0.33
RHC = right heart catheterization; PAH = pulmonary arterial hypertension; SVT = supra ventricular tachycardia; WHO = world health organization functional class of dyspnea;
ECG = electrocardiogram; RBBB = right bundle branch block; LBBB = left bundle branch block; LVEF = left ventricular ejection fraction; BNP = brain natriuretic protein;
MDRD = modiﬁcation of the diet in renal disease Formula. sPAP = systolic pulmonary arterial pressure; dPAP = diastolic pulmonary arterial pressure; mPAP = mean pulmonary
arterial pressure; PAWP = pulmonary artery wedge pressure; RVEDP = right ventricular end diastolic pressure; RAP = right atrial pressure; CO = cardiac output; CI = cardiac
index; PVR = pulmonary vascular resistance; WU = woods units.
a LDL (low-density lipoprotein–cholesterol) ≥1 g/L or patient under statin therapy.
b Active smoking or stopped for less than 3 years.
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In this work we tried to improve the management of patients diag-
nosed with pre-capillary pulmonary hypertension with a secondary in-
crease in PAWP onwhich very little has been published yet.Wewanted
to conﬁrm that this phenomenon was frequent and to determine if it
had any prognostic value. Secondly, we hoped that identifying all the
possible causes of such phenomenon could help improve daily practice.
4. Results
We included 90 patients with pre-capillary PH. The patient selection
process is depicted in Fig. 1. At the end of follow-up, 60 patients had
RHCs showing stable PAWP ≤15 mm Hg (group A), while 30 patients
had one or more RHC showing PAWP N15 mm Hg (group B). Mean
time of follow-up was 3.0 ± 1.6 years.
Demographical data are presented in Table 1 for the overall popula-
tion. Mean age was similar in both groups (65.2 ± 15.7 for group A and
65.2 ± 12.3 for group B; p = 0.99). Female patients represented 56.7%and 50% of groups A and B respectively (p = 0.55). Medical records
and cardiovascular risk factors were comparable. Etiologies of pulmo-
nary hypertension were equally distributed in both groups. A majority
of patients presented aWHO functional class III or IV at ﬁrst clinical ex-
amination. LVEF was within normal range for all patients (all ≥ 50%).
PAH subgroup was the most represented in overall population (54 pa-
tients, mean age 61.3 ± 15.6) and was equally distributed between
group A: 37 (61.7%) and group B: 17 (56.7%), (p= 0.64). Demographi-
cal data in this subgroup were comparable between both groups
(Table 2). Etiologies of PAH are represented in Fig. 2. There were signif-
icantly fewer patients with idiopathic PAH in group B than in group A (3
vs. 19 patients respectively, OR 0.20 [0.05–0.82]; p = 0.026). Among
other etiologies of PAH, no signiﬁcant differences were highlighted.
One patient from group A had a double etiology of PAH (anorexigen in-
take and scleroderma). No patient had PAH-speciﬁc treatments at the
time of enrollment. The concomitant cardiovascular medications taken
at this time were comparable in groups A and B. Hemodynamic data
at ﬁrst RHC in overall population showed comparable values between
both groups (Table 1). PAWP was 10.9 ± 2.7 mm Hg in group A
Fig. 2. Etiologies of PAH in groups A and B.
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was found between the numbers of patients with a PAWP≥ 12mmHg
(43.3% of patients in group A versus 36.7% in group B). Hemodynamic
parameters were also comparable when considering PAH sub group.
We detailed clinical and paraclinical data at ﬁrst RHC showing a
PAWP N 15 mm Hg for Group B patients in overall population (Table 3).
Themean time for the elevation of PAWPwas 1.1±1 year after initial di-
agnosis. Mean number of catheterization was 1.7 ± 0.74/year, while the
mean number of RHC showing an elevation of PAWP above 15 mm Hg
was 37% [17–64%]. At the time of the rise of PAWP, therewere signiﬁcant-
ly more patients under diuretics (p = 0.0042) and global posology of
furosemide was higher (10 ± 38 mg initially versus 22 ± 41 mg, p =
0.0006). Furosemide was only stopped for one patient who had a
daily dose of 40 mg. PAH speciﬁc treatments at this time were bosentan
(n = 16; 53.3%), sildenaﬁl (n = 19; 63.3%), epoprostenol (n = 2; 6.7%)
and ambrisentan (n = 3; 11.8%). Thirteen patients were under bi-
therapy. Clinical examination at this time showed an improvement of
dyspnea: 60% of patients with WHO functional class I or II versus 26.7%
initially (p = 0.013). Mean PAWP was 22.8 ± 4.1 mm Hg.
Neither severe valvulopathy nor left ventricular systolic dysfunction
was diagnosed. TTE allowed identiﬁcation of ﬁve cases of ventricular
interdependence (16.7%). Two patients (6.7%) had a new onset of SVT
at the time of their ﬁrst RHC showing a PAWP N15 mm Hg as 3 (10%)
patients had SVT at initial RHC and at elevation of PAWP (p = 0.25).No patient had dysthyroidism. We noticed that 4 patients had a new
onset of high cardiac output. Among these, three developed anemia
with a mean drop of hemoglobin of 2 g/dL while another one had a
worsening of hypoxemia. A veno-occlusive disease was diagnosed
in one patient (3.3%) with scleroderma. She was found to have a
PAWP N15 mm Hg three months after the introduction of PAH speciﬁc
treatment. Four patients from group B already had CAD diagnosed at
the beginning of the study. One patient had a myocardial infarction
without ST segment elevation but she refused coronarography and
was treated medically. Among the patients who had a coronarography
during follow-up, an asymptomatic CAD was found in 3 (37.5%) of
them. The cause of the secondary elevation of PAWP was considered
unknown in 14 patients (46.7%). Clinical and paraclinical data at ﬁrst
RHC showing a PAWP N15 mm Hg in PAH subgroup are detailed in
Table 4.
Logistic regression analysis of initial data to predict the evolution of a
patient towards group A or group B in overall population and in PAH
patients did not show any signiﬁcant difference. General linear model
multivariate analysis did not allow one to identify baseline factors
associated with maximal PAWP variation in the whole population.
The Kaplan–Meier survival curve (Fig. 3) showed no signiﬁcant
difference between both groups (p = 0.42), even when considering
only PAH sub group (p = 0.18). All-cause mortality at the end of
follow-up was 34% in overall population and 30% in PAH sub group. In
Table 3
Data at diagnosis RHC and at ﬁrst RHC showing an elevation of PAWP in the overall population.
Group B (n = 30) Data at ﬁrst RHC Data at ﬁrst PAWP N 15 mm Hg p
Age 65.2 ± 12.3 66.7 ± 12.2 –
Weight 74.3 ± 15.2 74.6 ± 15.7 0.8
Diuretics
Patients treated with diuretics 10 (33.3%) 22 (73.3%) 0.0045
Furosemide (mg) 10 ± 38 22 ± 41 0.0006
Thiazide diuretics (mg) 1.7 ± 4.3 1.7 ± 5.4 1.00
Spironolactone (mg) 3.3 ± 14.3 2.5 ± 13.7 0.32
Clinical presentation
WHO I + II 8 (26.7%) 18 (60%) 0.013
WHO III 18 (60%) 10 (33.3%) 0.03
WHO IV 4 (13.3%) 2 (6.7%) 0.62
Mean WHO 2.9 ± 0.6 2.4 ± 0.7 0.0041
6 min Walking Test (meters) 306.24 ± 126.15 331 ± 128.7 0.24
Biology
BNP (pg/mL) 392.8 ± 492.7 311.3 ± 462.3 0.51
Troponin (μg/L) 0.05 ± 0.06 0.04 ± 0.06 0.55
MDRD (mL/min/1.73 m2) 65.6 ± 23.3 67 ± 26.6 0.60
MDRD ≤ 30 mL/min/1.73 m2 2 (6.7%) 2 (6.7%) 1.00
Echocardiography
LVEF (%) 64.8 ± 8.8 64.2 ± 6.2 0.52
Pericardial effusion 2 (6.7%) 2 (6.7%) –
Hemodynamics
Heart rate (bpm) 76 ± 14 75 ± 12 0.62
sPAP (mm Hg) 71.9 ± 17.5 71.7 ± 19.4 0.93
dPAP (mm Hg) 29.3 ± 8.7 28.8 ± 7.3 0.75
mPAP (mm Hg) 44.7 ± 10.1 44.3 ± 10.6 0.86
PAWP (mm Hg) 10.4 ± 2.4 22.8 ± 4.1 0.0001
RVEDP (mm Hg) 13.7 ± 5.7 16 ± 4.6 0.051
RAP (mm Hg) 9.5 ± 6.2 13 ± 3.7 0.0028
CO (L/min) 4.7 ± 1.49 5.9 ± 1.5 b0.0001
CI (L/min/m2) 2.6 ± 0.7 3.3 ± 0.7 b0.0001
CI ≥ 3.9 L/min/m2 1 (3.3%) 5 (17%) 0.12
PVR (WU) 8.2 ± 4.2 4.4 ± 2.3 b0.0001
Indexed PVR (WU/m2) 4.66 ± 2.71 2.5 ± 1.5 b0.0001
mPAP-PCWP (mm Hg) 34.3 ± 10.7 21.6 ± 9.7 b0.0001
dPAP-PCWP (mm Hg) 18.9 ± 9.4 5.6 ± 6.4 b0.0001
LVEF = left ventricular ejection fraction; BNP = brain natriuretic protein; MDRD = modiﬁcation of the diet in renal disease formula. SVT = supra ventricular tachycardia.
sPAP = systolic pulmonary arterial pressure; dPAP = diastolic pulmonary arterial pressure; mean pulmonary arterial pressure; PAWP = pulmonary artery wedge pressure;
RVEDP = right ventricular end diastolic pressure; RAP = right atrial pressure; CO = cardiac output; CI = cardiac index; PVR = pulmonary vascular resistance. WU = woods units
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WHO functional class IV (HR 4.12 [1.78–9.54]; p = 0.0009), smoking
(HR 4.80 [2.08–11.05]; p = 0.0002) and a low MDRD (HR 0.97 [0.95–
0.98]; p b 0.0001) were risk markers for all-cause mortality. Survival
curves adjusted for age, sex, RAP, RVP, mPAP, 6MWT, MDRD, smoking
and WHO functional class IV were not signiﬁcantly different (p =
0.67). For PAH subgroup, multivariable Cox regression only identiﬁed
WHO functional class IV (HR 5.65 [1.94–16.46]; p = 0.0015) as a risk
marker of all-cause mortality. Survival curves adjusted for age, sex,
RAP, RVP, mPAP, 6MWT, MDRD, smoking, WHO functional class IV
were not signiﬁcantly different either (p = 0.10).
5. Discussion
Our study showed that in a population of patients diagnosed with a
pre-capillary PH, a secondary elevation of PAWP above 15 mm Hg was
frequent, occurring in one third of our cohort even when considering
only the PAH sub group. Patients with idiopathic PAH seemed less
exposed to such a phenomenon. No other demographic, biological or
hemodynamic predictive factor was identiﬁed for a secondary PAWP
increase, but several possible causes were highlighted. This PAWP
elevation had no impact on survival in our cohort.
Left heart disease is one of the most common causes of PH and the
presence of PH is associated with a poor prognosis in these patients
[6]. Up to 70% of patients with isolated diastolic dysfunction may
develop PH. Conversely, a secondary increase of PAWP in pre-capillary
PH patients was not well described in the literature. This phenomenon
affected 30% of our cohort and this result is reinforced by a recentstudy from the REVEAL registry where Frost et al. [2] showed that
among 3128 patients, 30% of those with a PAWP ≤15 mm Hg had a
PAWP ≥16 mm Hg at follow-up. The mean age of our population was
65 years oldwhich can be partially explained by the fact thatwe includ-
ed patients with PH spanning all etiologies in opposition to the latter
study that focused on group 1 PH. Nevertheless, most recent data
suggest that demographics of patients with PAH are changing. In the
COMPERA registry [7], launched in 2007 and including patients with
all forms of pre-capillary PH, mean age was the same as in our study.
For PAH patients, mean age was 61.3 ± 15.6 years and the percentage
of women was 63%, comparable to the latest registries [7,8]. Patients
were severely burdened with cardiovascular risk factors which can be
partially explained by the mean age of the population. Systemic hyper-
tension was the most frequent cardiovascular risk factor which is
consistent with REVEAL registry [8]. Nearly 13% of our PAH patients
had a history of coronary artery disease (CAD), which is similar than
the British Registry [9]. This can probably be explained by the high
prevalence of cardiovascular risk factors as CAD in PAH patients is
associatedwith older age, systemic hypertension and dyslipidemia [10].
Coronary angiogram was regularly performed when PAWP was
N15 mm Hg in PH patients with multiple risk factors as myocardial
ischemia can promote diastolic heart failure [11] and could be asymp-
tomatic in such patients (3 CAD out of 8 coronary angiograms per-
formed in this indication). Changes in volume status and diuresis
explaining transient elevation of PAWP were unlikely because most of
the patients had diuretics and/or greater dose at follow-up as compared
to baseline. Ventricular interdependence in severe forms of PH ap-
peared as a solid cause for an elevated PAWP [12]. It can lead to left
Table 4
Data at diagnosis RHC and at ﬁrst RHC showing an elevation of PAWP for PAH subgroup.
Group B (n = 17) Data at ﬁrst RHC Data at ﬁrst PCWP N 15 mm Hg p
Age 60.3 ± 12.1 61.8 ± 11.8 –
Weight 74.3 ± 17.8 75.6 ± 16.8 0.58
Diuretics
Patients treated with diuretics 5 (29.4%) 14 (82.3%) 0.012
Furosemide (mg) 9.4 ± 21.3 36.5 ± 23.7 0.0023
Thiazide diuretics (mg) 0 0 –
Spironolactone (mg) 5.9 ± 18.8 4.4 ± 18.2 0.33
Clinical presentation
WHO I + II 4 (23.5%) 11 (64.7%) 0.03
WHO III 10 (58.8%) 4 (23.5%) 0.03
WHO IV 3 (17.6%) 2 (11.8%) 0.56
Mean WHO 2.9 ± 0.7 2.4 ± 0.8 0.02
Six min Walk Test (meters) 293 ± 114.7 349 ± 114.1 0.17
Biology
BNP (pg/mL) 442 ± 532.3 222.5 ± 310 0.2
Troponin (μg/L) 0.05 ± 0.08 0.03 ± 0.02 0.21
MDRD (mL/min/1.73 m2) 72.2 ± 23.6 75.3 ± 23.6 0.43
MDRD ≤ 30 mL/min/m2 0 (0%) 0 (0%) –
Echocardiography
LVEF (%) 65.6 ± 10 64.8 ± 6.4 0.58
Pericardial effusion 0 (0%) 0 (0%) –
Hemodynamics
sPAP (mm Hg) 71.6 ± 20.2 68.9 ± 22.5 0.38
dPAP (mm Hg) 31.2 ± 9.9 29.4 ± 8.7 0.49
mPAP (mm Hg) 45.9 ± 11.6 44.2 ± 12.4 0.59
PAWP (mm Hg) 10.6 ± 2.7 22.6 ± 4.2 b0.0001
RVEDP (mm Hg) 13.7 ± 7.3 16.3 ± 4.8 0.13
RAP (mm Hg) 10 ± 7.7 13.5 ± 4.1 0.07
CO (L/min) 4.76 ± 1.73 6.31 ± 1.58 0.0002
Heart rate (bpm) 77 ± 14 77 ± 12 0.84
CI (L/min/m2) 2.59 ± 0.74 3.45 ± 0.71 0.0002
CI ≥ 3.9 L/min/m2 1 (5.9%) 4 (23.5%) 0.25
PVR (WU) 8.4 ± 4.7 4 ± 2.4 0.0003
Indexed PVR (WU/m) 4.78 ± 3 2.28 ± 1.59 0.004
mPAP-PCWP (mm Hg) 35.3 ± 12.6 21.6 ± 10.7 0.0002
dPAP-PCWP (mm Hg) 20.6 ± 10.9 6 ± 5.9 b0.0001
LVEF = left ventricular ejection fraction; BNP = brain natriuretic protein; MDRD = modiﬁcation of the diet in renal disease formula; sPAP = systolic pulmonary arterial pressure;
dPAP = diastolic pulmonary arterial pressure; mean pulmonary arterial pressure; PAWP = pulmonary artery wedge pressure; RVEDP = right ventricular end diastolic pressure;
RAP = right atrial pressure; CO = cardiac output; CI = cardiac index; PVR = pulmonary vascular resistance; WU = wood units.
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in a left ventricular underﬁlling [15] and to myocardial remodeling
towards an atrophy of the left ventricle [16]. Other factors that could
elevate PAWP were a new onset of high cardiac output [17] and the
occurrence of atrial ﬁbrillation, although this last factor might be
controversial. Indeed, Clark et al. [18] showed that the irregularity of
atrial ﬁbrillation, independent of heart rate, decreased CO and increased
both PAWP and RAP. Medical records of SVT and SVT on ECG at the time
of initial RHC were comparable in both groups and occurrence of SVT
was higher at elevated PAWP, but not signiﬁcantly. This result drives
us to the conclusion that SVT might only be an indirect factor of an
elevation of left ventricular end diastolic pressure (LVEDP). The loss of
atrial systole and the tachycardia induced by atrial ﬁbrillation could
just unmask an underlying diastolic cardiomyopathy. Although our
study was not designed to prove it, one could suppose that left ventric-
ular diastolic dysfunction (LVDD) was revealed by PH-speciﬁc medica-
tions improving ﬂow through the pulmonary vascular bed [2]. The
difﬁculty of diagnosing such diastolic dysfunction is a daily challenge
in clinical practice. Its assessment needs a complete analysis of diastolic
function by echocardiography performed on the same day as RHC and
results from the association of multiple parameters [11] that depend
on age, heart rate and body size [19]. Moreover, in these patients with
chronic PH, BNP did not help discriminate between pre- and post-
capillary PH as it was elevated in both conditions. Nevertheless, the ab-
sence of systolic left ventricular dysfunction or severe left valvulopathy
in patients with an elevated PAWP argues for an underlying diastolic
dysfunction.
LVDD was frequently described in echographic studies on PAH
patients [20]. But sometimes, resting PAWP can be normal despite LVdiastolic dysfunction, especially when patients have been treated with
diuretics. Updated guidelines on the diagnosis and deﬁnition of pre-
capillary hypertension published 2013 [21] insisted on the fact that
PAWP is not a constant number but a biological variable that is affected
by various facts including ﬂuid balance and intrathoracic pressure. This
is why challenging LV diastolic function by a ﬁlling or exercise test
performed at ﬁrst RHC could be useful, especially as demographic risk
factors for diastolic dysfunction such as hypertension or obesity [22,
23] could not help to differentiate our two groups initially and that a
PAWP ≤15 mm Hg at ﬁrst RHC may not rule out heart failure with
preserved LV ejection fraction deﬁnitely. A recent retrospective study
showed that ﬂuid challenge by an intravenous ﬂuid bolus of 0.5 L of
normal saline given during 5 to 10 min was safe and that it could
unmask occult pulmonary venous hypertension in 22.2% of patients
with a PAWP b15 mm Hg initially [24].
The high prevalence of systemic hypertension could also support
the idea of a progressive vasculopathy or common substrate affecting
both pulmonary and systemic vascular beds [8]. Indeed, it was recently
found that children with idiopathic PAH also presented systemic
endothelial dysfunction [25]. The theory of a common substrate for PH
and left ventricular diastolic dysfunction could explain the difﬁculty to
ﬁnd baseline predictive factors of PAWP elevation in our study. Why
patients with idiopathic PAH were less subject to an elevation of
PAWP above 15 mm Hg could be explained by the intrinsic nature of
their PH. In comparison, scleroderma not only can be associated with
PAH but alsowith LVDD or veno-occlusive disease that could contribute
to an increase of pulmonary capillary pressure [26,27].
Finally, survival was not affected by a secondary elevation of PAWP
in our study, even when considering only PAH patients, although this
Fig. 3. A) Kaplan–Meier survival curve for groups A and B in the overall population
(p = 0.42).
168 J. Wain-Hobson et al. / IJC Heart & Vessels 4 (2014) 161–169result should be tempered by the size of our cohort. On the contrary, in
the REVEAL study [8], the outcome of PAH patients whose PAWP had
increased to ≥19 mmHg at follow-up was worse, regardless of initial
PAWP (that could be up to 18 mm Hg). Furthermore, as we only
selected patients with at least 2 RHC, we might have excluded the
most severe cases of PH leading to fatal ventricular interdependency
before a second RHC could be performed. WHO functional class IV
appeared as a poor prognosis factor as previously described in the
literature [28].5.1. Limits
Themain limit of our studywas the small size of our cohort. Second-
ly, diastolic dysfunctionwas identiﬁed hemodynamically in the absence
of systolic left ventricular dysfunction or severe valvulopathy. Full
echographic analysis of diastolic dysfunction was not available as it
was not always performed on the same day as RHC. PAWP's reliability
to predict LVEDP can also be discussed. Halpern et al. showed that
approximately 50% of patients presumed to have pre-capillary PH
based on PAWP might be found to have pulmonary venous hyper-
tension based on LVEDP [29]. Nevertheless, they took the numerical
value of PAWP given by the catheterization report without reviewing
hemodynamical tracings although an important interobserver varia-
bility in the interpretation of hemodynamical tracings exists [30].In our study, all tracings were reviewed by specialists and we excluded
doubtful PAWP curves. Ryan et al. [31] showed that careful physician's
determination of end-expiratory PAWP upon review of waveforms
can prevent misclassiﬁcation of PH. We should also note that using
the 15 mmHg PAWP threshold to deﬁne pre-capillary pulmonary
hypertension might lead to an initial misclassifying of patients with an
underlying heart failure with preserved LV ejection fraction [21]. The
15 mmHg limit stays however the actual threshold recommended.
Furthermore, transpulmonary gradient (TPG) and diastolic pressure
gradient (DPG) initially measured in our patients were high, driving
us to the conclusion that they were well selected with a pre-capillary
PH [32]. The reliability of PAWP still remains a point of discussion for
Dana Point group 4 patients asmeasurement of PAWP could be affected
if performed by occluding a pulmonary vessel burdened with distal
thromboembolism [33].
6. Conclusion
Our study provided anobservational analysis of the secondary rise of
PAWP phenomenon in patients diagnosed with a pre-capillary PH. This
phenomenon, that could be transient, appeared to be frequent even in
the PAH sub group. Patients with idiopathic PAH were at lower risk of
developing a PAWP N 15 mmHg during follow-up which could be ex-
plained by the intrinsic nature of their pulmonary arterial hypertension.
We did not identify any other baseline predictive factors of a second-
ary elevation of PAWP in our population, possibly underlining the close
pathophysiology between PAH and LV diastolic dysfunction. Or maybe,
this could reﬂect the tremendous difﬁculty to precisely distinguish true
pre-capillary PH from occult pulmonary venous hypertension using
PAWP alone. Nevertheless, we highlighted several possible etiologies
that should be sought in the case of an increase of PAWP during
follow-up,manyofwhichmaybe linked to an underlying LVDD. Further
prospective studies with complete diastolic echocardiographic function
analysis, direct LV-end diastolic pressure measurement and volume or
exercise challenge during initial RHC may help to better identify and
treat these patients.
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